Lacosamide for the treatment of partial-onset seizures

Expert Review of Neurotherapeutics

Volumn 12, Issue 6, 2012, Pages 645-655

  Biton, Victor ^a  

^a Arkansas Epilepsy Program   (United States)

Author keywords

antiepileptic drug; epilepsy; intravenous; lacosamide; partial onset seizures

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 ISOENZYME; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PLACEBO; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

AGE; ATAXIA; BLURRED VISION; COORDINATION DISORDER; DIPLOPIA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOCAL EPILEPSY; GENDER; HEADACHE; HUMAN; NAUSEA; NYSTAGMUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SOMNOLENCE; TREMOR; VISUAL DISORDER; VOMITING;

ACETAMIDES; ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; EPILEPSIES, PARTIAL; HUMANS; TREATMENT OUTCOME;

EID: 84861740392     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.50     Document Type: Review

References (74)

1. Jacoby A, Baker GA. Quality-of-life trajectories in epilepsy: a review of the literature. Epilepsy Behav. 12(4), 557-571 (2008
2. Jennum P, Gyllenborg J, Kjellberg J. The social and economic consequences of epilepsy: a controlled national study. Epilepsia 52(5), 949-956 (2011
3. Meador KJ, French J, Loring DW, Pennell PB. Disparities in NIH funding for epilepsy research. Neurology 77(13), 1305-1307 (2011
4. Neligan A, Bell GS, Johnson AL, Goodridge DM, Shorvon SD, Sander JW. The long-term risk of premature mortality in people with epilepsy. Brain 134(Pt 2), 388-395 (2011
5. Neligan A, Bell GS, Shorvon SD, Sander JW. Temporal trends in the mortality of people with epilepsy: a review. Epilepsia 51(11), 2241-2246 (2010
6. Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 9(7), 464-468 (2000
7. Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs 66(14), 1817-1829 (2006 (Pubitemid 44584005)
8. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE Clinical Guidance 137 (2012
9. French JA, Kanner AM, Bautista J et al.; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62(8), 1252-1260 (2004 (Pubitemid 38526035)
10. Glauser T, Ben-Menachem E, Bourgeois B et al. ILAE treatment guidelines: evidencebased analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47(7), 1094-1120 (2006 (Pubitemid 44086745)
11. VIMPAT® (lacosamide) Prescribing Information. UCB, Inc., Smyrna, GA, USA (2011
12. VIMPAT® (lacosamide) Summary of Product Characteristics for Lacosamide. UCB Pharma, S.A., Belgium (2011
13. Beyreuther BK, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stöhr T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 13(1), 21-42 (2007 (Pubitemid 46697839)
14. Choi D, Stables JP, Kohn H. Synthesis and anticonvulsant activities of N-benzyl-2- acetamidopropionamide derivatives. J. Med. Chem. 39(9), 1907-1916 (1996
15. Park KD, Morieux P, Salomé C et al. Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors. J. Med. Chem. 52(21), 6897-6911 (2009
16. Wang Y, Brittain JM, Jarecki BW et al. In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation. J. iol. Chem. 285(33), 25296-25307 (2010
17. Errington AC, Stöhr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 73(1), 157-169 (2008 (Pubitemid 350294207)
18. Sheets PL, Heers C, Stoehr T, Cummins TR. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)- Nbenzyl- 3-methoxypropanamide], lidocaine, and carbamazepine. J. Pharmacol. Exp. Ther. 326(1), 89-99 (2008 (Pubitemid 351872141)
19. Wolff C, Carrington B, Varrin-Doyer M et al. Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP-2). CNS Neurosci. Ther. (2011) (In Press
20. Wang Y, Brittain JM, Wilson SM, Khanna R. Emerging roles of collapsin response mediator proteins (CRMPs) as regulators of voltage-gated calcium channels and synaptic transmission. Commun. Integr. Biol. 3(2), 172-175 (2010
21. Hensley K, Venkova K, Christov A, Gunning W, Park J. Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol. Neurobiol. 43(3), 180-191 (2011
22. Stöhr T, Kupferberg HJ, Stables JP et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 74(2-3), 147-154 (2007 (Pubitemid 46654745)
23. Biton V. Lacosamide for the treatment of diabetic neuropathic pain. Expert Rev. Neurother. 8(11), 1649-1660 (2008
24. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48(7), 1308-1317 (2007 (Pubitemid 47063096)
25. Chung S, Sperling MR, Biton V et al.; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 51(6), 958-967 (2010
26. Halász P, Kälviäinen R, Mazurkiewicz- Beldzinska M et al.; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 50(3), 443-453 (2009
27. Cawello W, Bonn R. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers. J. Clin. Pharmacol. doi:10.1177/ 0091270011426875 (2011) (Epub ahead of print
28. Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J. Clin. Pharmacol. 50(4), 459-471 (2010
29. Thomas D, Scharfenecker U, Nickel B, Doty P, Cawello W, Horstmann R. Low potential for drug drug interaction of lacosamide. Epilepsia 48, 104 (2007
30. Chung S, Ben-Menachem E, Sperling MR et al. Examining the clinical utility of lacosamide: pooled analyses of three Phase II/III clinical trials. CNS Drugs 24(12), 1041-1054 (2010
31. Doty P, Biton V, Fountain NB et al. Safety and tolerability of lacosamide: a summary of adverse events in epilepsy clinical trials. Neurology 72, A225 (2009
32. Cramer J, Borghs S, De Backer M, Doty P. Improved seizure severity, health-realted quality of life and health status reported by patients during long-term treatment with locasimide: analysis of pooled open-label data. Presented at: The 65th Annual Meeting of the American Epilepsy Society. Baltimore, MD, USA, 6-11 December 2011.
33. De La Loge C, Borghs S, Eggert-Formella A, Cramer J, Mueller K, Doty P. Improvement in patient-reported outcomes seen in patients responding to lacosamide: pooled QOLIE-31, SSQ, and PGIC data from three phase II/III clinical trials. Neurology 74(Suppl. 2) (2010
34. Sake JK, Hebert D, Isojärvi J et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 24(12), 1055-1068 (2010
35. Husain A, Chung S, Faught E, Isojarvi J, McShea C, Doty P. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. Epilepsia 53(3), 521-528 (2012
36. Rosenfeld W, Fountain NB, Kaubrys G et al. Lacosamide: long-term safety and efficacy in partial-onset seizures. Presented at: The 29th International Epilepsy Congress. Rome, Italy, 28 August-1 September 2011.
37. Rosenow F, Kelemen A, Ben-Menachem E, McShea C, Isojarvi J, Doty P. Presented at: 29th International Epilepsy Congress. Rome, Italy, 28 August-1 September 2011.
38. Isojarvi J, Rosenow F, Faught E, Hebert D, Doty P. Lacosamide efficacy in partialonset seizures with and without secondary generalization: a pooled analysis of three Phase II/III trials. Neurology 74(Suppl. 2) (2010
39. Brodie MJ, CoVanis A, Gil-Nagel A et al. Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav. 21(4), 331-341 (2011
40. Brodie MJ, Sills GJ. Combining antiepileptic drugs-rational polytherapy? Seizure 20(5), 369-375 (2011
41. Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations: have newer agents altered clinical outcomes? Epilepsy Res. 98(2-3), 194-198 (2012
42. Hillenbrand B, Wisniewski I, Jürges U, Steinhoff BJ. Add-on lacosamide: a retrospective study on the relationship between serum concentration, dosage, and adverse events. Epilepsy Behav. 22(3), 548-551 (2011
43. Stephen LJ, Kelly K, Parker P, Brodie MJ. Adjunctive lacosamide in clinical practice: sodium blockade with a difference? Epilepsy Behav. 22(3), 499-504 (2011
44. Villaneuva V, López-Gamariz E, López- Trigo J et al. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav. 23, 298-304 (2012
45. Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia 39(1), 81-88 (1998 (Pubitemid 28116846)
46. Cramer JA, Baker GA, Jacoby A. Development of a new seizure severity questionnaire: initial reliability and validity testing. Epilepsy Res. 48(3), 187-197 (2002 (Pubitemid 34252903)
47. Krauss G, Ben-Menachem E, Mameniskiene R et al.; SP757 Study Group. Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures. Epilepsia 51(6), 951-957 (2010
48. Chen LL, Haneef Z, Dorsch A, Keselman I, Stern JM. Successful treatment of refractory simple motor status epilepticus with lacosamide and levetiracetam. Seizure 20(3), 263-265 (2011
49. Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav. 14(2), 429-431 (2009
50. Turpín-Fenoll L, Millán-Pascual J, Navarro-Muñoz S, del Saz-Saucedo P, Rueda-Medina I. [The use of oral lacosamide in a patient with refractory partial epileptic status]. Rev. Neurol. 50(10), 603-606 (2010
51. Albers JM, Möddel G, Dittrich R et al. Intravenous lacosamide - an effective add - on treatment of refractory status epilepticus. Seizure 20(5), 428-430 (2011
52. Goodwin H, Hinson HE, Shermock KM, Karanjia N, Lewin JJ 3rd. The use of lacosamide in refractory status epilepticus. Neurocrit. Care 14(3), 348-353 (2011
53. Höfler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia 52(10), e148-e152 (2011
54. Kellinghaus C, Berning S, Immisch I et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol. Scand. 123(2), 137-141 (2011
55. Koubeissi MZ, Mayor CL, Estephan B, Rashid S, Azar NJ. Efficacy and safety of intravenous lacosamide in refractory nonconvulsive status epilepticus. Acta Neurol. Scand. 123(2), 142-146 (2011
56. Parkerson KA, Reinsberger C, Chou SH, Dworetzky BA, Lee JW. Lacosamide in the treatment of acute recurrent seizures and periodic epileptiform patterns in critically ill patients. Epilepsy Behav. 20(1), 48-51 (2011
57. Rantsch K, Walter U, Wittstock M, Benecke R, Rösche J. Efficacy of intravenous lacosamide in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Seizure 20(7), 529-532 (2011
58. Fernandez EM, Franck AJ. Lacosamide for the treatment of refractory status epilepticus. Ann. Pharmacother. 45(11), 1445-1449 (2011
59. Degiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav. 18(3), 322-324 (2010
60. Krause LU, Brodowski KO, Kellinghaus C. Atrioventricular block following lacosamide intoxication. Epilepsy Behav. 20(4), 725-727 (2011
61. Nizam A, Mylavarapu K, Thomas D et al. Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy. Epilepsia 52(10), e153-e155 (2011
62. Rosenfeld W, Husain A, Rosenow F, McShea C, Isojarvi J, Doty P. Evaluation of long-term treatment with lacosamide for partial-onset seizures: a pooled analysis of open-label extension trials. Presented at: 29th International Epilepsy Congress. Rome, Italy, 28 August-1 September 2011.
63. LeRoy RF, Krauss G, Fountain NB, Dilley D, D'Cruz N, Doty P. Lacosamide: long-term safety in partial onset seizures. Presented at: 29th International Epilepsy Congress. Rome, Italy, 28 August-1 September 2011.
64. Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 49(3), 418-424 (2008 (Pubitemid 351294527)
65. Fountain N, Krauss G, Isojarvi J, Dilley D, Doty P, Rudd G. A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in patients with partial-onset seizures. Epilepsia 51(Suppl. 4), 123, abs p416 (2010
66. Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium channelblocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav. 20(1), 20-23 (2011
67. Marik PE, Varon J. The management of status epilepticus. Chest 126(2), 582-591 (2004 (Pubitemid 39093446)
68. Lowenstein DH, Alldredge BK. Status epilepticus. N. Engl. J. Med. 338(14), 970-976 (1998 (Pubitemid 28152839)
69. Shorvon S, Baulac M, Cross H, Trinka E, Walker M; TaskForce on Status Epilepticus of the ILAE Commission for European Affairs. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia 49(7), 1277-1285 (2008 (Pubitemid 351991403)
70. Gavatha M, Ioannou I, Papavasiliou AS. Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav. 20(4), 691-693 (2011
71. Guilhoto LM, Loddenkemper T, Gooty VD et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr. Neurol. 44(6), 414-419 (2011
72. Heyman E, Lahat E, Levin N, Berkovitch M, Gandelman-Marton R. Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. Eur. J. Paediatr. Neurol. 16(1), 15-19 (2012
73. Shiloh-Malawsky Y, Fan Z, Greenwood R, Tennison M. Successful treatment of childhood prolonged refractory status epilepticus with lacosamide. Seizure 20(7), 586-588 (2011
74. Brodie MJ. Antiepileptic drug therapy the story so far. Seizure 19, 650-655 (2010)